Search Results | Blood | American Society of Hematology

1-20 of 606

Sort by

Sort Order Select

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

DOI: https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Stephen J Noga, MD PhD, Robert M. Rifkin, MD, Sudhir Manda, MD, Ruemu Ejedafeta Birhiray, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 3168.

DOI: https://doi.org/10.1182/blood-2019-124784

Published: 2019

Journal Articles

Prognostic Value of Diffusion-Weighted Magnetic Resonance Imaging in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation

Elena Fernández-Poveda, Valentin Cabañas, MD, Maria José Moreno, Miguel Blanquer Blanquer, MD PhD, José M Moraleda, MD

Blood (2019) 134 (Supplement_1): 3146.

DOI: https://doi.org/10.1182/blood-2019-130804

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

DOI: https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Valentina S Caputo, Nikolaos Trasanidis, Xiaolin Xiao, Mark E Robinson, Alexia Katsarou, Kanagaraju Ponnusamy, Aristeidis Chaidos, Holger W Auner, MD PhD, Irene Roberts, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 4329.

DOI: https://doi.org/10.1182/blood-2019-125047

Published: 2019

Journal Articles

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Rong Fu, Jr., PhD, Fengjuan Jiang, Hui Liu, Zhaoyun Liu, Siyang Yan, Jin Chen, Zonghong Shao, MD, Qing Shao

Blood (2019) 134 (Supplement_1): 4416.

DOI: https://doi.org/10.1182/blood-2019-127022

Published: 2019

Journal Articles

Structural Basis of Vitamin K Antagonism

Weikai Li, PhD, Shixuan Liu, Shuang Li

Blood (2019) 134 (Supplement_1): 482.

DOI: https://doi.org/10.1182/blood-2019-127324

Published: 2019

Journal Articles

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

Galen Goldscheitter, BS, BA, Robert Klein, MD, Jason A Taylor, MD PhD

Blood (2019) 134 (Supplement_1): 4916.

DOI: https://doi.org/10.1182/blood-2019-130698

Published: 2019

Journal Articles

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Shoshana Revel-Vilk, MD, Tama Dinur, PhD, Majdolen Istaiti, Dafna Frydman, DMV, Michal Becker-Cohen, MSc, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4712.

DOI: https://doi.org/10.1182/blood-2019-123000

Published: 2019

Journal Articles

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Neal J Weinreb, MD, Timothy M Cox, MD, Pramod K. Mistry, MD PhD FRCP, Joel Charrow, MD, Elena Lukina, MD PhD Professor, Meredith C. Foster, ScD, M. Judith Peterschmitt, MD

Blood (2019) 134 (Supplement_1): 4859.

DOI: https://doi.org/10.1182/blood-2019-127337

Published: 2019

Journal Articles

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Poornima Ramadas, MBBS, Ajay Tambe, MBBS, Mijung Lee, MD

Blood (2019) 134 (Supplement_1): 5463.

DOI: https://doi.org/10.1182/blood-2019-131577

Published: 2019

Journal Articles

Adiponectin Inhibits the Differentiation and Maturation of Osteoclasts Via mTOR Pathway in Multiple Myeloma

Rong Fu, Jr., PhD, Liu Zhaoyun, Hui Liu, Yanqi Li, Yangyang Wang, Rui Xing, Fu Mi, Zonghong Shao, MD, Jia Song, Chenhuan Xiang

Blood (2019) 134 (Supplement_1): 5521.

DOI: https://doi.org/10.1182/blood-2019-126861

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

DOI: https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

DOI: https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

DOI: https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

DOI: https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

DOI: https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis

Marie Hu, MD, Gaurav Goyal, MBBS, Jason Young, MD, Karen Rech, MD, N. Nora Bennani, MD, Mithun Vinod Shah, MD PhD, Robert Vassallo, MD, Jay H Ryu, MD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 1667.

DOI: https://doi.org/10.1182/blood-2019-132104

Published: 2019

Journal Articles

BRAF V600E-Positive Precursors As Molecular Markers of Bone Marrow Involvement in Pediatric Langerhans Cell Histiocytosis

Ko Kudo, MD, Rika Kanezaki, PhD, Akie Kobayashi, MD, Tomohiko Sato, MD PhD, Takuya Kamio, MD PhD, Shinya Sasaki, MD PhD, Imamura Masaru, MD PhD, Chihaya Imai, MD PhD, Masahiro Irie, MD PhD, Yoji Sasahara, MD PhD, Kumiko Ando, MD, Harumi Kakuda, MD PhD, Takehiko Doi, MD PhD, Hiroshi Kawaguchi, MD PhD, Kazuko Kudo, MD PhD, Hirokazu Kanegane, MD PhD, Kiminori Terui, MD PhD, Tsutomu Toki, PhD, Etsuro Ito, MD PhD

Blood (2019) 134 (Supplement_1): 3588.

DOI: https://doi.org/10.1182/blood-2019-127536

Published: 2019

Journal Articles

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

Anna Benedetta Dalla Palma, MD, Laura Notarfranchi, MD, Jessica Crosara, MD, Mario Pedrazzoni, MD, Fabrizio Accardi, MD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, PhD, Paola Storti, PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 1795.

DOI: https://doi.org/10.1182/blood-2019-128252

Published: 2019

NARROW

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Prognostic Value of Diffusion-Weighted Magnetic Resonance Imaging in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Structural Basis of Vitamin K Antagonism

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Adiponectin Inhibits the Differentiation and Maturation of Osteoclasts Via mTOR Pathway in Multiple Myeloma

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis

BRAF V600E-Positive Precursors As Molecular Markers of Bone Marrow Involvement in Pediatric Langerhans Cell Histiocytosis

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only